MY163516A - Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents - Google Patents

Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Info

Publication number
MY163516A
MY163516A MYPI2010006096A MYPI2010006096A MY163516A MY 163516 A MY163516 A MY 163516A MY PI2010006096 A MYPI2010006096 A MY PI2010006096A MY PI2010006096 A MYPI2010006096 A MY PI2010006096A MY 163516 A MY163516 A MY 163516A
Authority
MY
Malaysia
Prior art keywords
polymorphs
metal chelation
novel salts
chelation agents
desazadesferrithiocin polyether
Prior art date
Application number
MYPI2010006096A
Other languages
English (en)
Inventor
Amy E Tapper
Hugh Y Rienhoff
Stephan D Parent
Patricia Andres
Jason A Hanko
Huamin Zhang
Original Assignee
Ferrokin Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrokin Biosciences Inc filed Critical Ferrokin Biosciences Inc
Publication of MY163516A publication Critical patent/MY163516A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MYPI2010006096A 2008-07-14 2009-07-14 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents MY163516A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8057208P 2008-07-14 2008-07-14
US15257209P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
MY163516A true MY163516A (en) 2017-09-15

Family

ID=41550988

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010006096A MY163516A (en) 2008-07-14 2009-07-14 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents

Country Status (13)

Country Link
US (4) US8063227B2 (enExample)
EP (1) EP2303853A4 (enExample)
JP (1) JP2011528037A (enExample)
KR (1) KR20110039347A (enExample)
CN (2) CN102149700A (enExample)
AU (1) AU2009271074B2 (enExample)
CA (1) CA2728636A1 (enExample)
IL (2) IL210294A (enExample)
MX (1) MX2011000486A (enExample)
MY (1) MY163516A (enExample)
NZ (2) NZ605452A (enExample)
WO (1) WO2010009120A2 (enExample)
ZA (1) ZA201100311B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270473A1 (en) 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
BRPI0610644B8 (pt) 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
US8324397B2 (en) 2007-03-15 2012-12-04 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
MY163516A (en) 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) * 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
US20130053387A1 (en) * 2010-05-04 2013-02-28 FerroKin BioScience, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
AU2012347595A1 (en) * 2011-12-09 2014-06-26 Ferrokin Biosciences, Inc. Oral formulations for treating metal overload
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
EP2928469A4 (en) * 2012-12-07 2016-11-02 Ferrokin Biosciences Inc POLYMORPHIC FORMS OF DESAZADESFERRITHIOCIN ANALOGS
AU2014228308A1 (en) * 2013-03-15 2015-08-27 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
JP6838966B2 (ja) * 2013-11-22 2021-03-03 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． デスフェリチオシン類似体およびその使用
KR102497273B1 (ko) * 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
JP2018515475A (ja) * 2015-04-27 2018-06-14 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 代謝的にプログラムされた金属キレーターおよびその使用
US10446309B2 (en) 2016-04-20 2019-10-15 Vishay Dale Electronics, Llc Shielded inductor and method of manufacturing
CN107119083A (zh) * 2017-04-28 2017-09-01 江苏梦得新材料科技有限公司 一种生物酶法制备聚二硫二丙烷磺酸钠的方法
CN107174917A (zh) * 2017-05-01 2017-09-19 蒋里军 粘土矿物治霾方法及其摩天大楼治霾烟囱
CN108264892A (zh) * 2017-12-21 2018-07-10 东北农业大学 一种用于释放地下油质材料的表面活性剂的组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
AT500490A1 (de) * 2001-10-16 2006-01-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten thiazolinen und deren zwischenprodukte
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20060069134A1 (en) * 2002-10-01 2006-03-30 Kaneka Corporation Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same
AU2003270473A1 (en) 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
CA2538159A1 (en) 2003-09-09 2005-03-17 University Of Florida Research Foundation, Inc. Polyamine-metal chelator conjugates
BRPI0610644B8 (pt) * 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
US20080138440A1 (en) * 2006-11-29 2008-06-12 Cormedix Inc. Methods of diagnosing and alleviating gadolinium toxicity
JP2010512398A (ja) 2006-12-12 2010-04-22 ユニバーシティ オブ フロリダ デスフェリチオシン類縁体アクチニド除染剤
US8324397B2 (en) 2007-03-15 2012-12-04 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
MY163516A (en) * 2008-07-14 2017-09-15 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) * 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
JP5925679B2 (ja) 2009-08-25 2016-05-25 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド デスフェリチオシンポリエーテル類似体およびその使用
US20130053387A1 (en) * 2010-05-04 2013-02-28 FerroKin BioScience, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
IL210294A0 (en) 2011-03-31
US20110160257A1 (en) 2011-06-30
US8710087B2 (en) 2014-04-29
AU2009271074B2 (en) 2014-10-30
CN103435569A (zh) 2013-12-11
EP2303853A2 (en) 2011-04-06
MX2011000486A (es) 2011-08-03
US20120202857A1 (en) 2012-08-09
US8063227B2 (en) 2011-11-22
KR20110039347A (ko) 2011-04-15
CN103435569B (zh) 2015-08-19
CA2728636A1 (en) 2010-01-21
ZA201100311B (en) 2011-12-28
AU2009271074A1 (en) 2010-01-21
CN102149700A (zh) 2011-08-10
WO2010009120A8 (en) 2011-02-24
US8829197B2 (en) 2014-09-09
IL210294A (en) 2014-04-30
NZ605452A (en) 2014-05-30
IL231558A0 (en) 2014-04-30
US8846731B2 (en) 2014-09-30
NZ590302A (en) 2013-02-22
EP2303853A4 (en) 2011-08-10
WO2010009120A3 (en) 2010-04-22
US20120270911A1 (en) 2012-10-25
US20100137383A1 (en) 2010-06-03
JP2011528037A (ja) 2011-11-10
WO2010009120A2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
MY163516A (en) Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
WO2011140232A3 (en) Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents
WO2011017054A3 (en) Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents
IN2012DN01233A (enExample)
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MX2009010407A (es) Derivados fluorados de deferiprona.
MY164731A (en) Compound
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
GEP201706656B (en) 2-thiopyrimidinones
IL193252A0 (en) N-hydroxyacrylamide compounds
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2131849A4 (en) COMPOSITIONS AND METHODS OF DISTRIBUTING AGENTS AGAINST CANCER
MX2011011618A (es) Agentes terapeuticos 713.
EA201000141A1 (ru) Новые триазены для лечения рака
MX2010001303A (es) Compuestos terapeuticos.
TN2011000678A1 (en) Fluorinated derivatives of 3-hydroxypyridin-4-ones
MX2009005912A (es) Derivados de etilamina-fenilo heterociclilo sustituidos, su preparacion y uso como medicamentos.
MX2012015102A (es) Agentes terapeuticos 976.
PL1874410T3 (pl) Odbarwiająca lub rozjaśniająca kompozycja kosmetyczna zawierająca co najmniej jedną oksazolinę jako składnik aktywny
ZA200706705B (en) Phenylbenzoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic uses thereof
SI1904511T1 (sl) Homogemcitabini
IL191690A0 (en) Therapy of malignant neoplasias